Download Files:
Tauro-β-muricholic acid-d4 (sodium)
SKU
HY-135103S-1mg
Category Isotope-Labeled Compounds
Tags Cancer, FXR;Isotope-Labeled Compounds, Metabolic Enzyme/Protease;Others
Products Details
Product Description
– Tauro-β-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].
Web ID
– HY-135103S
Shipping
– Room temperature
Molecular Formula
– C26H40D4NNaO7S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Sayin SI, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013 Feb 5;17(2):225-35.|[3]Wahlström A, et al. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res. 2017 Feb;58(2):412-419.|[4]Fu T, et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019 Feb 21;176(5):1098-1112.e18.
Molecular Weight
– 541.71
SMILES
– C[C@@H]([C@]1(CC[C@]2([C@@]3([C@H]([C@H]([C@@]4(C([2H])([C@@H](C([2H])(C[C@@]4([C@]3(CC[C@@]21C)[H])C)[2H])O)[2H])[H])O)O)[H])[H])[H])CCC(NCCS(=O)(O[Na])=O)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– FXR;Isotope-Labeled Compounds
Pathway
– Metabolic Enzyme/Protease;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.